Intercept Not Changing NDA Refiling Plans After OCA Misses NASH Cirrhosis Endpoint

Failed experiment
Failure in cirrhotic NASH will not scuttle Intercept's overall plans in the disease • Source: Shutterstock

More from Clinical Trials

More from R&D